Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

@article{Garon2014RamucirumabPD,
  title={Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial},
  author={Edward B. Garon and Tudor Eliade Ciuleanu and Oscar Arrieta and Kumar Prabhash and Konstantinos N Syrigos and Tuncay Goksel and Keunchil Park and V. A. Gorbunova and Ruben Dario Kowalyszyn and Joanna Pikiel and Grzegorz Czyżewicz and Sergey V. Orlov and Conrad R. Lewanski and Michael Thomas and Paolo Bidoli and Shaker R. Dakhil and Steven J.M. Gans and Joo‐Hang Kim and Alexandru Călin Grigorescu and Nina A. Karaseva and Martin Reck and Federico Cappuzzo and Ekaterine Alexandris and Andreas I. Sashegyi and Sergey Yurasov and Maurice P{\'e}rol},
  journal={The Lancet},
  year={2014},
  volume={384},
  pages={665-673}
}

Figures and Tables from this paper

Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV

R’+ D is a highly effective and safe third-line treatment after failure of second-line programmed cell death protein 1/programmed cell death-ligand 1 (PD1/PD-L1)-derived ICI therapy irrespective of NSCLC histology and is a very suitable option for patients not treated with first-line ICI.

Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV

D+R is an effective and safe 2nd line treatment after failure of 1st line CTx+ICI irrespective of NSCLC histology, however, patients with a KRAS mutation did not benefit from D+R in terms of PFS and will require further investigations.

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

It is suggested that second-line ram+doc may be effective regardless of prior treatment with platinum-based chemotherapy plus a taxane, pemetrexed, gemcitabine or bevacizumab, and overall, ram+ doc is clinically beneficial across a wide range of patients with metastatic NSCLC who have progressed after various front-line therapies.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)

  • H. NokiharaS. Lu T. Tamura
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
S-1 is equally as efficacious as docetaxel and offers a treatment option for patients with previously treated advanced NSCLC and the upper limit of 95% CI of HR fell below 1.2, confirming non-inferiority of S-1 to docetAXel.
...

References

SHOWING 1-10 OF 37 REFERENCES

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin–gemcitabine, and the PFS benefit did not translate into a significant OS benefit, possibly due to high use of efficacious second-line therapies.

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Patients who received docetaxel had a longer time to progression and a greater progression-free survival at 26 weeks and the 1-year survival was significantly greater with D75 than with the control treat...

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  • N. HannaF. Shepherd P. Bunn
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-liners when available.

Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

Addition of ramucirumab to docetaxel in HER2-negative advanced breast cancer did not meaningfully improve important clinical outcomes.

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer

  • J. HainsworthL. Fang C. Azzoli
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2011
The rate of PH was low, the number of patients in this study was also low, and no new safety signals were identified, so treatment of squamous NSCLC with bevacizumab should be considered experimental.

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m(2), the benefits of docetAXel therapy outweigh the risks.